EUROPEAN COMMISSION

Brussels,4.6.2018
C(2018) 3674 final

PUBLIC VERSION

To the notifying party:

Subject: **Case M.8887 – PLATINUM EQUITY / LIFESCAN**
Commission decision pursuant to Article 6(1)(b) of Council Regulation (EC) No 139/2004[1] and Article 57 of the Agreement on the European Economic Area[2]

Dear Sir or Madam,

1. On 4 May 2018, the European Commission received notification of a proposed concentration pursuant to Article 4 of the Merger Regulation by which Platinum Equity ("Platinum", USA), acquire within the meaning of Article 3(1)b of the Merger Regulation sole control of Lifescan Inc., part of Johnson&Johnson (USA) by way of purchase of shares and assets through a special purpose vehicle.[3]

2. The business activities of the undertakings concerned are:

   – for Platinum: a private investment firm, specialised in the merger, acquisition and operation of companies in a broad range of businesses, including information technology, telecommunications, logistics, metal services, manufacturing and distribution at global level.

   – for LifeScan: provides blood glucose monitoring systems for home and hospital use under the global brand OneTouch. The OneTouch portfolio includes personal blood glucose meters, testing strips, lancets, point of care testing systems and integrated digital solutions.

1 OJ L 24, 29.1.2004, p. 1 (the 'Merger Regulation'). With effect from 1 December 2009, the Treaty on the Functioning of the European Union ('TFEU') has introduced certain changes, such as the replacement of 'Community' by 'Union' and 'common market' by 'internal market'. The terminology of the TFEU will be used throughout this decision.

2 OJ L 1, 3.1.1994, p. 3 (the 'EEA Agreement').

3 Publication in the Official Journal of the European Union No C 170, 17.05.2018, p. 12.

Commission européenne, DG COMP MERGER REGISTRY, 1049 Bruxelles, BELGIQUE
Europese Commissie, DG COMP MERGER REGISTRY, 1049 Brussel, BELGIË

Tel: +32 229-91111. Fax: +32 229-64301. E-mail: COMP-MERGER-REGISTRY@ec.europa.eu.

3. After examination of the notification, the European Commission has concluded that the notified operation falls within the scope of the Merger Regulation and of paragraph 5(b) of the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004.[4]

4. For the reasons set out in the Notice on a simplified procedure, the European Commission has decided not to oppose the notified operation and to declare it compatible with the internal market and with the EEA Agreement. This decision is adopted in application of Article 6(1)(b) of the Merger Regulation and Article 57 of the EEA Agreement.

For the Commission

(Signed)
Johannes LAITENBERGER
Director-General

4 OJ C 366, 14.12.2013, p. 5.